Interventional Oncology · IR Playbook

Percutaneous Ablation of Liver Tumors

Percutaneous thermal ablation destroys primary or metastatic liver tumors by placing image-guided radiofrequency electrodes, microwave antennas or cryoprobes within the target. It is a potentially curative, parenchyma-sparing treatment for appropriately selected small tumors and may also provide bridging, salvage or local-control therapy. Oncological success depends principally on complete tumor coverage with a quantitatively verified circumferential margin while avoiding biliary, vascular and extrahepatic injury.

Learning objectives

• Select liver tumors suitable for curative-intent percutaneous ablation through multidisciplinary review.
• Choose between RFA, MWA and cryoablation according to tumor size, location, heat-sink exposure and structures at risk.
• Plan a trajectory and applicator configuration that achieves complete three-dimensional tumor coverage with an adequate margin.
• Apply hydrodissection, artificial ascites, pneumodissection or biliary protection when required.
• Recognize incomplete ablation and major hemorrhagic, biliary, infectious and collateral-organ complications.

Indications

• Very-early or early hepatocellular carcinoma, particularly a solitary tumor ≤3 cm or up to three tumors each ≤3 cm, when ablation is selected over resection or transplantation by the multidisciplinary team.
• Hepatocellular carcinoma bridging or downstaging before liver transplantation when ablation can provide complete viable-tumor treatment.
• Small colorectal liver metastases, generally ≤3 cm, when all target disease can be eradicated with adequate margins; randomized evidence supports ablation as an alternative to resection in carefully selected patients with up to ten ≤3 cm liver-only metastases.
• Limited non-colorectal liver metastases, including neuroendocrine, breast, renal, melanoma or sarcoma metastases, when local treatment is appropriate within a disease-specific multidisciplinary strategy.
• Local recurrence after previous ablation or resection when repeat complete ablation remains technically and oncologically appropriate.
• Selected unresectable intrahepatic cholangiocarcinoma or other primary hepatic malignancy for local control when established curative options are unsuitable.
• Symptom-directed or cytoreductive treatment of selected functioning neuroendocrine liver metastases after appropriate peri-procedural hormonal prophylaxis.

Absolute contraindications

• Uncorrectable bleeding diathesis for a high-bleeding-risk percutaneous procedure.
• Uncontrolled infection or cholangitis.
• Absence of a safe percutaneous access route when protective displacement cannot be achieved.
• Inability to encompass the tumor with a sufficient margin without unacceptable injury to critical structures.

Relative contraindications

• Tumor larger than 3 cm, because overlapping ablations or combination therapy may be required and local progression risk increases.
• Tumor abutting the central bile ducts, bowel, gallbladder, stomach, diaphragm or cardiac structures.
• Bilioenteric anastomosis, sphincterotomy, biliary stent or drainage catheter causing biliary colonization and markedly increased abscess risk.
• Severe hepatic decompensation, refractory ascites or inadequate functional liver reserve.
• Extensive intrahepatic or uncontrolled extrahepatic disease unless a defined palliative or oligoprogressive indication exists.
• Large vessel adjacency causing heat sink, particularly for RFA.
• Cardiac implantable electronic device when monopolar RFA is planned without electrophysiology assessment.
• Inability to cooperate with breath-holding when controlled ventilation, respiratory gating or motion compensation is unavailable.

Equipment

• US system with convex probe, sterile cover and optional contrast-enhanced US or fusion-navigation capability
• CT, CT-fluoroscopy, cone-beam CT, stereotactic CT or MRI guidance platform as selected
• Thermal-ablation generator and manufacturer-compatible 14–17G electrode, antenna or cryoprobe
• Additional matched applicators for parallel placement or overlapping ablation of larger or irregular targets
• RFA dispersive grounding pads for monopolar systems with skin-preparation materials
• Cryoablation console with argon and active-thaw gas or manufacturer-specific gas supply
• 18–22G access or hydrodissection needle and extension tubing
• 5% dextrose solution for non-ionic hydrodissection during RFA; saline, carbon dioxide or balloon displacement when appropriate to the modality
• Temperature probes for monitoring vulnerable structures when displacement alone is insufficient
• Coaxial biopsy system, commonly 17G introducer with 18G core needle, when tissue confirmation is required
• Contrast agent, injector and image-registration or ablation-confirmation software
• Hemostatic material, drainage catheters, embolization capability and resuscitation equipment for complications

Procedure steps

1. Verify the target, diagnosis, treatment intent and required tumor-specific margin against the current multiphasic imaging. Confirm that the selected applicator configuration can cover the tumor plus margin and review the rescue plan for bleeding or collateral injury.Pearl: Margin adequacy, not merely visible tumor necrosis, is the principal technical goal.
2. Position the patient to shorten the trajectory, separate vulnerable organs and provide stable access. Establish deep sedation or general anesthesia and use reproducible breath-holds, apnea or respiratory control when required.Pearl: Prone or decubitus positioning may move bowel away from a subcapsular target and improve posterior access.
3. Identify the lesion and critical structures with US, CT, fusion, cone-beam CT or MRI. If conspicuity is inadequate, use contrast-enhanced US, arterial-phase CT, transarterial marking or navigation rather than approximating the target.
4. Use hydrodissection, artificial ascites, pneumodissection, balloon interposition or organ decompression to create a stable protective plane when necessary. For RFA, prefer non-ionic 5% dextrose near the active electrode because ionic saline conducts current.Pearl: Confirm separation throughout the ablation because injected fluid can redistribute with patient position and respiration.
5. When histology will alter management, obtain a coaxial core biopsy before ablation through a trajectory that will lie within the final ablation zone. Tissue is not routinely required for an imaging-diagnostic HCC when accepted non-invasive criteria apply.Pearl: A single coaxial route limits capsular punctures and permits subsequent tract treatment.
6. Advance the selected electrode, antenna or cryoprobes into the planned three-dimensional positions under continuous or intermittent imaging. Use parallel applicators and adequate spacing for synergistic ablation when supported by the device, and verify every tip before energy delivery.Pearl: Place the most technically difficult applicator first before edema, hemorrhage, gas or ice obscures landmarks.
7. Apply the manufacturer-prescribed power, duration and impedance or temperature protocol. RFA heats tissue through alternating-current ionic agitation, MWA produces electromagnetic heating and cryoablation uses freeze–thaw cycles with the lethal zone lying inside the visible ice-ball margin.Pearl: MWA is generally faster and less affected by perfusion-mediated heat sink than RFA, whereas cryoablation provides direct ice-ball visualization.
8. Monitor applicator position, ablation-zone growth and adjacent structures during energy delivery. Use temperature monitoring or active protective techniques near critical organs, and stop or reposition if the predicted zone threatens a structure at risk.
9. Obtain immediate contrast-enhanced CT or MRI and compare it with registered pre-ablation imaging. Quantitatively assess the margin in three dimensions whenever software is available and classify each target as A0, A1 or A2.Pearl: Immediate confirmation permits correction during the same anesthetic and is preferred to discovering an inadequate margin at follow-up.
10. For A1 or A2 findings, reposition or add applicators and perform overlapping ablation when safe. Repeat contrast-enhanced assessment and document the final margin classification for every treated tumor.
11. During withdrawal, perform tract ablation for RFA or MWA when supported by the device to improve hemostasis and reduce viable-cell displacement. Cryoablation does not provide equivalent heat-based tract cauterization, so withdraw carefully and scrutinize the tract and liver capsule for bleeding. Obtain final imaging for hemorrhage, pneumothorax, visceral injury and vascular patency.

Complications

• Post-ablation syndrome
• Hemorrhage or hemoperitoneum
• Bile-duct injury, biloma or biliary stricture
• Liver abscess and sepsis
• Collateral gastrointestinal, gallbladder or diaphragmatic injury
• Portal or hepatic venous thrombosis and hepatic infarction
• Hepatic decompensation or liver failure
• Pleural injury, pneumothorax or pleural effusion
• Grounding-pad skin burn during monopolar RFA
• Cryoreaction or cryoshock
• Needle-tract tumor seeding

Exam pearls

• Ablation is a margin procedure: destroying the visible tumor without an adequate circumferential margin is not an oncologically complete treatment.
• A0, A1 and A2 are the ablation counterparts of complete adequate treatment, complete but inadequate-margin treatment and residual unablated tumor.
• RFA is most susceptible to heat sink; MWA produces faster, larger heating; cryoablation offers direct ice-ball visualization but its visible edge is not the lethal isotherm.
• The bile duct is less tolerant of thermal injury than a large blood vessel; central duct proximity may be more dangerous than vascular proximity.
• For colorectal liver metastases, >5 mm is the minimum critical margin and 10 mm is the preferred oncological target when safe.
• Bilioenteric anastomosis, sphincterotomy and biliary stenting convert the ablation cavity into a high-risk substrate for delayed liver abscess.
• Immediate quantitative three-dimensional margin confirmation enables supplementary ablation before the patient leaves the procedure room.

Viva questions

What defines an A0 liver-tumor ablation?

A0 means that the entire tumor is covered by the ablation zone with a quantitatively sufficient circumferential tumor-free margin. A1 means complete tumor coverage but an insufficient margin, whereas A2 means that part of the tumor remains unablated.

What margin should be achieved around a liver tumor?

A minimum margin of at least **5 mm** should be achieved in every direction. For colorectal liver metastases, a **10 mm** margin provides optimal local control when it can be obtained safely.

Why is microwave ablation less affected by heat sink than RFA?

MWA produces an electromagnetic field that directly agitates water molecules and can generate higher temperatures over a larger volume more rapidly. Continued tissue heating is therefore less dependent on electrical current conduction and is less vulnerable to cooling by adjacent blood flow.

Does the visible cryoablation ice ball represent the lethal ablation zone?

No. The visible ice-ball edge is approximately the 0°C boundary, while reliable cell death requires substantially colder temperatures lying several millimetres inside it. The ice ball must therefore extend beyond the tumor and intended lethal margin.

Why is a central hilar tumor dangerous to ablate?

The central bile ducts are highly susceptible to thermal injury and may develop necrosis, biloma, cholangitis or delayed stricture. Tumors within approximately 1 cm of a major duct require active protection, an alternative modality or reconsideration of ablation.

Which patients have the highest risk of liver abscess after ablation?

Patients with an incompetent sphincter of Oddi from bilioenteric anastomosis, sphincterotomy, biliary stenting or drainage have colonized bile ducts and the greatest risk. They require protocolized broad-spectrum prophylaxis, commonly extending for 5–10 days.

Why is 5% dextrose preferred for hydrodissection during RFA?

Five-percent dextrose is non-ionic and does not conduct radiofrequency current. Ionic saline can conduct current away from the electrode and unintentionally increase heating of adjacent tissues.

What is the best imaging endpoint immediately after ablation?

Contrast-enhanced CT or MRI should show no residual tumor enhancement and should permit three-dimensional registration of the pre-ablation tumor with the post-ablation zone. Quantitative margin assessment with confirmation software is preferred over visual side-by-side inspection alone.

References